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The In-Vitro bioassay was developed for the determination of biological activity of 
Follicle Stimulating Hormone (FSH) using recombinant Chinese hamster ovary (CHO) 
based cell line that expresses the human FSH receptor (CHOSI FSHR CRELuc B-5) as well 
as luciferase reporter construct. The signal measured here comes from the luciferase 
activity that is dependent on the FSH stimulation. The present work focuses on an In-
Vitro receptor-binding assay in which binding of FSH to its receptors (expressed on CHO 
cells) gives a dose and/or activity-dependent production of cAMP quantified by luciferase 
assay system. This kind of In-Vitro bioassay is used to determine the biological potency 
of FSH molecule. The assay is simple, has high throughput (performed in 96 half well area 
plates), and shows reproducible dose-response curves in the concentration range of 10.5-
0.02 mIU/mL. With overall repeatability 6.5% and spike recovery of 100.7% and the assay 
has high precision and accuracy. Specificity was demonstrated by the lake of activity of 
assaying a variety of proteins manufactured by Intas. The In-Vitro cell based reporter 
gene assay has the preferred characteristics which makes it suitable to determine the 
biological activity of Recombinant Human Follicle Stimulating Hormone rHuFSH. 
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The Glycoprotein hormone, follicle 
stimulating hormone (FSH), plays a vital role 
in reproductive function as it stimulates the 
development of the ovarian follicle and 
spermatogenesis. FSH has considerable 
potential for treatment of both male and 
female infertility (Bishop et al., 1995). 
Gonadotrophic cells of the anterior pituitary 
are responsible for the production of Follicle 
stimulating hormone (FSH) and released into 
the circulation and plays a vital role in the 
regulation and maintenance of essential 
reproductive processes such as 
gametogenesis, follicular development and 
 




ovulation. The mode of communication of 
cells is through chemical signals. These 
chemical signals in the form of signaling 
molecules bind to specific receptors in the 
target cell. This molecule   receptor union 
activates receptor protein and results in 
transduction of the signal carried by specific 
extra cellular messenger. A highly cell 
specific and sensitive response is obtained by 
the activation of receptor proteins. These 
activation triggers a cascade of reactions 
which is amplified and the active response is 
initiated. The structure of signaling molecule 
plays an essential role in receptor binding, 
activation and to initiate the sensitive signal 
transduction pathway. FSH is a glycoprotein 
hormone which is responsible for the 
reproductive function such as development 
of the ovarian follicle and spermatogenesis. 
FSH is 34 kDa glycolhormone consist two 
non-covalently linked polypeptide the α- and 
β- subunits.  
Assessment of biological activity is very 
important aspect in the quality control of 
therapeutic proteins. FSH binding to its 
receptor on gonadal cells increases 
intracellular levels of cAMP by activating 
adenylyl cyclase (Richards, 1994). cAMP is 
the primary second messenger for the trophic 
effects of FSH (Means et al., 1980).  
It was shown earlier that rHuFSH 
elicited a dose–dependant increase in 
luciferase activity (Albanese et al., 1994). 
Granulosa aromatase bioassay (GAB) (Jia  et 
al. 1986a, 1986b) and Sertoli cell bioassay 
(SCB) (Padmanabhan  etal. 1987) for FSH has 
limited sensitivity involving non human cells 
for assays. Prior treatment of serum with 
polyethylene (Jia et al. 1986a, 1986b) is must 
in case of rate granulose cell assay whereas 
the immature rat Sertoli cell assay is valid 
over only a limited range of serum volumes 
(Padmanabhan et al. 1987).These assays are 
highly heterogeneous and not produced 
consistent results as they both are dependent 
upon the induction of aromatase and with 
this dissimilarity it is difficult to interpret the 
physiological significance of bioactivity 
(Christin-Maitre et al. 1996). To address these 
issues, we have demonstrated a unique 
bioassay to study the In-Vitro binding affinity 
and intrinsic bioactivity of rHuFSH using 
CHOSI-FSHR-Luc assay (Albanese et al., 
1994). 
Here we are reporting reporter gene 
cell based assay for rHuFSH which binds to 
recombinantly expressed human FSH 
receptor (rHuFSHR) in CHOSI cells. rHuFSH 
activate G protein complex and the alfa 
subunit of G-protein activates adenylate 
cyclase that converts ATP to cAMP. cAMP 
activates the cAMP response elements (CRE) 
that in turn regulates the luciferase reporter 
gene expression. The biological potency of 
any FSH sample can be determined by the 
measurement of this cAMP level via 
luciferase expression. The study was 
undertaken to develop the In-Vitro bioassay 
method and to qualify its performance 
demonstrating its suitability for the intended 
purpose. This exercise will further confirm 
the suitability of the method and demonstrate 
the reliability of the method through an 
extensive investigation of various parameters 
based on a written protocol and defined 
acceptance criteria. A precise and accurate 
assessment of biological activity of FSH is 
necessary for consistent and controlled 
manufacture of a well-characterized protein 
product (Workshop on well characterized 
Biopharmaceutical Product, 1995). An In-
Vitro bioassay based on the ability of FSH to 
bind its receptors when expressed on CHO 
cells gives the liner relationship between the 
relative luciferase unit (RLU) and number of 
bound rHuFSH to the receptors. This 
technique was developed to assess the 
potency of the therapeutic protein.  
 
Materials and methods 
Reagents 
Cell culture reagents MAM PF-2 (Bioconcept, 
Catalog No. 10-2F24-I), Pluronic F-68 
(Bioconcept, Catalog No. 5-75F02-H), Phenol 
 




Red (Sigma, Catalog No. P3532 or any cell 
culture tested), Dialyzed FBS (Invitrogen. 
Catalog No. 26400-044), Gentamicin 
(Ranbaxy), L-Glutamine (Sigma, Catalog 
No.G7513 or Hyclone, Catalog No. SH30034), 
Luciferase assay system (Promega, Catalog # 
E1501), Cell culture lysis buffer 5X (Promega, 
Catalog # E153A), White 96 well half area 
Assay Plates (Corning, Catalog No. 3688), 
Dilution Plate, 0.5 mL Polypropylene Plates 
(Nunc, Catalog No. 260251), Luminometer 
(Turner BioSystems USA). 
 
Growth and maintenance of CHOSI FSHR 
CRELuc B5-Cells 
The transformed CHO cell line CHOSI FSHR 
CRELuc B5-Cells received by technology 
transfer from Eugenix Biotechnologies, 
Switzerland. The cell line was grown in 
MAM PF-2 medium supplemented with L 
Glutamine (100X), Plurronic F-68, Phenol Red 
Solution and Gentamicin were cultured at 
370C in a humidified 5% CO2 incubator.  
 
Luminescence assay   
Reporter gene assay was performed using 
assay medium supplemented with MAM PF-
2, L Glutamine (100X), Plurronic F-68, FBS 
(Dialysed). Cells to be used should be 
minimum 24-36h from the last passaging. 
Cell count should be between 1x106 to 
1.5x106cells/mL and with viability greater 
than or equal to 90 %. Take the required 
volume of the cell suspension into 50 mL 
sterile centrifuge tube(s) and centrifuge at 350 
x g (equivalent to 1400 rpm) for three minutes 
at room temperature. Add 50 µL of the final 
cell suspension in a white 96 well half area 
Assay Plates (50,000 cell/well). Incubate 
plates at 370C for 30 min. After 30 min 
different concentrations of test component 
(dose number 1 to 8 in polypropylene 
“dilution” plate that is a concentration range 
of 10.5-0.02 mIU/mL) was added and 
incubated for ∼4 h. At the end of FSH 
incubation, cells were lysed (use 5X lysis 
buffer), incubated for 15 min at room 
temperature before reading the plate in a 
luminometer (Turner BioSystems USA). After 
these add 50 µl of luferase assay reagents 
which provided in the Luciferase assay 
system (Promega, Catalog # E1501). Specific 
activity was calculated using PLA software 




In-Vitro Cell based reporter gene assay for 
rHuFSH 
This In-Vitro assay requires generation of a 
stable cell line that will express the receptors 
for the target protein (FSH) on the surface of 
cells. These cells will then respond to varying 
degree of receptors which are engaged by the 
target protein i.e. as demonstrated in figure 1 
the concentration of FSH increased the 
corresponding RLU is also linearly increase. 
In this cell based assay rHuFSH binds to 
recombinantly expressed human FSH 
receptor (FSHR) in CHOSI cells. FSHR 
activates G protein complex and the alfa 
subunit of G-protein activates adenylate 
cyclase that converts ATP to cAMP. cAMP 
activates the cAMP response elements (CRE) 
that in turn regulates the luciferase reporter 
gene expression. The biological potency of 
any FSH sample can be determined by the 
measurement of this cAMP level via 
luciferase expression.  
The sigmoidal nature of the dose-response 
curve is typically found along with a 4.5 fold 
increase in relative luciferase unit. The EC50 is 
around 0.698 mIU/mL depending on the 
cultural condition and harvest density of 
cells. The lower limit of detection was found 
to be about 0.02 mIU/mL. Initial experiments 
were directed towards the development and 
optimization of assays for the potency 
determination of FSH.  These include the 
growth curve analysis of the cell line, sub 
culturing optimization, cell density, dose 
range optimization, Stimulation time with 
drug, Substrate and lysis buffer volume and 
effect of passage number. 
 






Figure 1 Responsiveness of the CHO FSH-R cell line to increasing amounts of rHuFSH (Gonal-
F, Serono). Experiments were carried out in 96 well culture plates in 50µl of cell suspension at a 
density of 50,000 cells/well for 4 h. Data shows that the rHuFSH preparations were able to 
induce a significant dose dependent luciferase Production.  
 
 
      
 
 
Figure 2 Linearity of method. Test bulk dilutions were prepared to get potencies, 160 % 
(8.80µg/mL), 140 % (7.15 µg/mL), 100 % (5.5 µg/mL), 80 % (4.4 µg/mL) and 60 % 
(3.3µg/mL). The samples were analyzed in In-Vitro Cell based reporter gene assay as if 
they were 5.5 µg/mL. Nine independent assays were performed by three analysts.  
  
 





The linearity of an analytical procedure is its 
ability (within a given range) to obtain a test 
results which are directly proportional to the 
concentration (amount) of analyte in the 
sample. Five potencies approximately evenly 
spaced over a log transformed potency scale, 
centered on 100% potency were selected. 
These were 60%, 80%, 100%, 130% and 160% 
potency level. Data from linearity 
experiments were analyzed as described 
below:  
Observed relative potency converted into 
observed % relative potency. Percent relative 
potency values transformed into natural-log 
values. Percent expected relative potency & 
values transformed into natural-log values. 
Calculated the mean of natural-log 
transformed data at each potency level.  
 
 
Table 1 Regression (R2), Intercept and Slope 







A linear relationship between the expected 
natural log (Ln) relative potencies and 
observed natural log (Ln) relative potencies 
was demonstrated in figure 2.Linear 
regression analysis of the data yielded 
regression (r2) 0.997, slope 0.92 and Intercept 
0.341 (table 1).  
 
Specificity 
The Specificity of the reporter gene assay was 
determined by assaying a variety of 
Hormones growth factors, glycoprotein and 
IgG like molecules manufactured by intas. 
Fig 3 shows that while rHuFSH displays a 
typical dose-response curve, none of the 
other protein molecules, like Peg IFN 2b, 
rHuPTH, rHuGCSF, rHu Peg GCSF, 
rHuEPO, Rituximab were active in the assay.  
Results from these experiments are 
represented in figure 3 and a table 2 shows 
the assay is specific to rHuFSH and other 
protein does not show responsiveness to the 
CHOSI FSHR CRELuc B5-Cells. 
 
   Table 2 Results of Method Specificity  
Sr.No. Sample Dose-response 
1 rHu FSH( NIBSC  standard) Observed 
2 rHu IFN alfa 2b Not observed 
3 rHu PTH Not observed 
4 rHu Peg GCSF Not observed 
5 rHu EPO Not observed 
6 rHu Rituximab Not observed 
 
Accuracy and precision 
Precision and accuracy are important 
parameters for judging the usefulness of an 
assay. The Precision of the Reporter gene 
assay was assessed by determining 
repeatability (intra-assay variation) and 
intermediate precision (inter-assay variation).  
Accuracy of the method should be assessed 
over the specified range of the method 
(Validation of Analytical Procedures: Text 
and Methodology, ICH Guideline: Q2 (R1)). 
Data obtained from testing of the five 
different simulated potency samples (spiked 
with assay media) from the method linearity 
assessment were utilized to assess the 
accuracy. rHuFSH was spiked with assay 
media to give expected activities of 160, 130, 
100, 80, and 60%.  The average % recovery 
must be 100 % ± 15 % per potency levels 
which were observed (Table 3).  
Precision can be defined as the 
closeness of agreement; here precision 
includes repeatability and intermediate 
precision. Repeatability of an analytical 
method describes the closeness of individual 
measures of an analyte when the procedure is 










Repeatability should be assessed using a 
minimum of nine determinations that cover 
the specified range (e.g. three 
concentrations/three replicate each) or by 
using a minimum of six determinations at the 
nominal potency level of 100% per assay. It is 
recommended that six assays to be 
performed to capture the overall 
repeatability. As per method capability, up to 
nine independent dilutions of the sample of 
the nominal potency level of 100% may be 
tested per assay. An assay included total 3 
plates. In each plate the test sample was 
analyzed twice at 100 % potency such that 6 
determinations of relative potency were 
obtained. Intra-plate, intra-assay precision 
and average repeatability were expressed in 
% GRSD. Table 4 represents Intra plate 
variation ranged from 2.5 % to 10.7 % GRSD 
and repeatability per assay ranged from 5.1 % 
to 7.2 % GRSD. Overall intra assay variation 
(average repeatability) observed was 6.5 % 
GRSD. 
 Intermediate precision is the degree 
of reproducibility of results obtained under 
different operating conditions like different 
days, different analysts etc. Three different 
analysts performed experiments over 
multiple days in order to assess the 
intermediate precision. Data obtained from 
the testing of five different simulated potency 
samples from the method linearity 





Figure 3 Specificity of Reporter Gene Assay. Indicated recombinant protein molecules 
were tested in the CHO FSH-R cell based reporter gene assay. 
 
Table 3 Percent recovery per potency level and average percent recovery 
% Potency level 
Average 
 Simulated Potency 160 130 100 80 60 
% Recovery 99.1 98.4 97.7 102.5 105.9 100.7 
Lower 95% Confidence Limit for 
the % Recovery 94.4 90.9 90.4 96.6 96.4 97.8 
Upper 95% Confidence Limit for 
the  % Recovery 104.0 106.4 105.6 108.9 116.4 103.6 
 
 




Table 4 Repeatability of reporter gene assay 
Variation 
Analyst 1 Analyst 2 Analyst 3 
Assay 1 Assay 2 Assay 3 
Intra-plate: Plate A 2.5% 2.6% 4.0% 
Intra-plate: Plate B 5.7% 10.7% 9.0% 
Intra-plate: Plate C 5.7% 0.8% 8.0% 
Inter-assay 5.1% 7.2% 6.9% 
Overall Repeatability  6.5% 
 
Table 5 Intermediate precision of reporter gene assay 
 
 
The % GRSD per an analyst per 
potency ranged from 5.0 % to 13.7 % for an 
analyst 1, 3.4 % to 17.6 % for an analyst 2, 0.7 
% to 10.5 % for an analyst 3 and the % GRSD 
per potency level ranged from 6.4 % to 13.0 
%. The variation with average intermediate 
precision is 9.4 % has been observed. 
  
Discussion 
Our was to develop a potency assay 
for quality control testing of recombinant 
human follicle stimulating hormone which is 
convenient, non-radioactive, accurate and 
precise. We have adopted cell based reporter 
gene assay to measure FSH bioactivity with a 
high degree of sensitivity and specificity. We 
have also demonstrated assay suitability, 
reproducibility, precision and accuracy for 
routine quality control testing. The most 
significant characteristic of the CHOSI cells 
(recombinant receptor cell line), is that the 
bioassay retains species specificity; dose not 
relies on primary tissue culture, no use of 
radioisotopes and can be completed within a 
5hr after hormone addition.  
 
This homologous bioassay which 
shows its specificity to rHuFSH only uses a 
luciferase gene (reporter gene) which is 
linked to the promoter of the glycoprotein 
hormone that is highly responsive to cAMP 
(S. Christin-Maitre et.al. 1996). Reporter gene 
cell based bioassay is simple and highly 
reproducible when multiple plates analyzed 
on different days, thus enabling its high 
throughput screening. The assay shows dose-
response curves in the concentration range of 
10.5 to 0.02 mIU/mL/well, with EC50 of 0.2-
0.45 mIU/mL. With intra assay variability 
6.5%, inter assay variability 9.4% and spike 
recoveries are 100.7%, the assay has the 
precision and accuracy requires for a potency 
% Potency Level 
Analyst 160 130 100 80 60 
Intermediate Precision ‘per Analyst per Potency level’ 
11.0 5.1 7.3 5.0 13.7 Analyst 1 
3.4 16.5 17.6 12.1 5.0 Analyst 2 
5.3 10.5 0.7 5.7 5.4 Analyst  3 
Intermediate Precision per Potency level 
6.4 10.7 10.5 8.1 13.0 NA 
Average Intermediate Precision 
9.4 NA 
 




assay. It has a high degree of specificity since 
variety other protein molecules dose not 
show any specificity. The main advantage of 
the reporter gene assay is the speed with 
which samples can be processed and the 
absence of long incubation time which helps 
to minimize the variability between samples. 
We also have checked certain robustness 
parameters like number of cells per well, Cell 
incubation, the time of incubation with drug, 
Reading at two different systems, which 
shows assay has the capacity to remain 
unaffected by small, but deliberate variations 
in the optimized parameters and provides an 
indication of its reliability during normal 
usage (data not shown). The recombinant 
follicle stimulating hormone is highly 
heterogeneous and the In-Vivo biological 
activity has depended on its being 
adequately sialylated (sialic acid content). 
rHuFSH is glycosyalated protein and  
produced from genetically modified 
organism not from chemical synthesis which 
may encounter process related and product 
related modification/changes. Analysis of 
desialylated rHuFSH sample shows high 
activities in In-Vitro (R.Patel, Unpublished 
data) as the molecules were shown full 
receptor binding in In-Vitro as molecules 
were shows full receptor binding because of 
the less steric hindrance (Galway, A.B. et.al. 
1990). This bioassay is allowing correlation of 
silaic acid content and biological activity In-
Vitro. This bioassay should provide new 
strategies for studies of rHuFSH structure-
function and efficient testing of rHuFSH 
produced recombinantly. 
 
We conclude stating that the cell 
based reporter gene assay is a reliable and 
sensitive assay for the biological 
characterization of the glycohormone and 
efficient testing of routine samples for batch 
release. Finally, the cell based In-Vitro 
reporter gene bioassay is simple, time-saving 
and useful for replicating assays with a large 
number of data points. 
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